Drug Profile
Research programme: tyrosine phosphatase inhibitors - Molecumetics
Latest Information Update: 14 Mar 2008
Price :
$50
*
At a glance
- Originator Molecumetics
- Class
- Mechanism of Action Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus
Most Recent Events
- 30 Nov 2002 No development reported - Preclinical for Diabetes mellitus in USA (unspecified route)
- 20 Apr 2001 Preclinical development for Diabetes mellitus in USA (Unknown route)